Brief: Vyne Therapeutics Announces Positive Data From Phase 1B Trial For Novel Bet Inhibitor Vyn201 In Patients With Nonsegmental Vitiligo

YARROW BIOSCIENCE

30/10/2023 11:09

Oct 30 (Reuters) - Vyne Therapeutics Inc  VYNE.O :
    * VYNE THERAPEUTICS ANNOUNCES POSITIVE DATA FROM PHASE 1B
TRIAL
FOR NOVEL BET INHIBITOR VYN201 IN PATIENTS WITH NONSEGMENTAL
VITILIGO
    * VYNE THERAPEUTICS INC - VYN201 WAS GENERALLY
WELL-TOLERATED WITH
NO CLINICALLY RELEVANT TREATMENT EMERGENT ADVERSE EVENTS ACROSS
ALL DOSE COHORTS
    * VYNE THERAPEUTICS - CLINICAL RESPONSE, RAPID ONSET OF
ACTION
SUGGEST VYN201 HAS POTENTIAL TO BE CATEGORY LEADER IN TREATMENT
OF NONSEGMENTAL VITILIGO
    * VYNE THERAPEUTICS INC - VYN201 IS EXPECTED TO ADVANCE INTO
A
PHASE 2B CLINICAL TRIAL IN FIRST HALF OF 2024

Source text for Eikon:  ID:nGNXbQQGhl 
Further company coverage:  VYNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))